Cat. No.: HY-103618

THZ531

38 Cited Publications

Customer Review

Based on 38 publication(s) in Google Scholar

THZ531 is a selective and covalent inhibitor of both CDK12 and CDK13 with IC₅₀s of 158 nM and 69 nM, respectively.

For research use only. We do not sell to patients.

Purity: 99.23%
CAS No.: 1702809-17-3
Formula: C₃₀H₃₂ClN₇O₂
Molecular Weight:558.07

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

THZ531 Chemical Structure

CAS No.: 1702809-17-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (38)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

THZ531 is a selective and covalent inhibitor of both CDK12 and CDK13 with IC₅₀s of 158 nM and 69 nM, respectively^[1].

IC₅₀ & Target^[1]

CDK12

158 nM (IC₅₀)

CDK13

69 nM (IC₅₀)

CDK7

8.5 μM (IC₅₀)

CDK9

10.5 μM (IC₅₀)

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Bel-7402	IC₅₀	650 nM Compound: THZ531	Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay	[PMID: 36905918]
BT-474	GI₅₀	0.044 μM Compound: THZ531	Antiproliferative activity against trastuzumab-sensitive HER2-positive human BT-474 cells by Cell Titer Glo assay Antiproliferative activity against trastuzumab-sensitive HER2-positive human BT-474 cells by Cell Titer Glo assay	[PMID: 38061230]
HCT-116	IC₅₀	89 nM Compound: THZ531	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay	[PMID: 36905918]
HeLa	IC₅₀	106 nM Compound: THZ531	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay	[PMID: 36905918]
JIMT-1	GI₅₀	1.84 μM Compound: THZ531	Antiproliferative activity against trastuzumab-resistant HER2-positive human JIMT-1 cells by Cell Titer Glo assay Antiproliferative activity against trastuzumab-resistant HER2-positive human JIMT-1 cells by Cell Titer Glo assay	[PMID: 38061230]
Kelly	IC₅₀	253.8 nM Compound: 10a; THZ531	Antiproliferative activity against human Kelly cells harboring CDK12 C1039F mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay Antiproliferative activity against human Kelly cells harboring CDK12 C1039F mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 33945934]
Kelly	IC₅₀	93 nM Compound: 10a; THZ531	Antiproliferative activity against human Kelly cells harboring wild type CDK12 assessed as reduction in cell viability incubated for 72 hrs by CelTiter-Glo assay Antiproliferative activity against human Kelly cells harboring wild type CDK12 assessed as reduction in cell viability incubated for 72 hrs by CelTiter-Glo assay	[PMID: 33945934]
L02	IC₅₀	119 nM Compound: THZ531	Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay	[PMID: 36905918]
MDA-MB-231	IC₅₀	133 nM Compound: THZ531	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 96 hrs by SRB assay	[PMID: 36905918]
MDA-MB-231	IC₅₀	17.9 μM Compound: 13; THZ531	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37478560]
MDA-MB-231	IC₅₀	7.1 μM Compound: 13; THZ531	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37478560]
MDA-MB-436	IC₅₀	18.1 μM Compound: 13; THZ531	Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37478560]
MDA-MB-436	IC₅₀	6.4 μM Compound: 13; THZ531	Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37478560]
MDA-MB-468	IC₅₀	14.4 μM Compound: 13; THZ531	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37478560]
MDA-MB-468	IC₅₀	5.8 μM Compound: 13; THZ531	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37478560]

In Vitro

The results from Kinase assays demonstrate that THZ531 potently inhibits CDK12 and CDK13 with IC₅₀s of 158 nM and 69 nM, respectively; whereas inhibition of CDK7 and CDK9 is more than 50-fold weaker with IC₅₀s of 8.5 and 10.5 μM, respectively. THZ531 treatment leads to a dramatic and irreversible decrease in Jurkat cell proliferation with an IC₅₀ of 50 nM. FACS cell cycle analysis following treatment with escalating doses of THZ531 displays a dose and time-dependent increase in the number of cells exhibiting sub-G1 content. At 50 nM THZ531, no increase in the percentage of apoptotic cells is observed over DMSO control for the time course of the experiment. Higher doses of THZ531 leads to pronounced Annexin V signal with 30 to 40% annexin V-positively stained cells by 72 hrs. A dramatic reduction in elongating Pol II following THZ531 treatment is also observed^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1702809-17-3
Appearance Solid
Molecular Weight 558.07
Formula C₃₀H₃₂ClN₇O₂
Color White to light yellow
SMILES

ClC(C(C1=CNC2=CC=CC=C12)=N3)=CN=C3N[C@@H]4CCCN(C(C5=CC=C(NC(/C=C/CN(C)C)=O)C=C5)=O)C4
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (38)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayRT-PCRIF

Sort by:

Journal Impact Factor

Nature

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. [Abstract]

2020 Sep;585(7824):293-297. PMID: 32494016

THZ531 purchased from MedChemExpress. Usage Cited in: Nature. 2020 Sep;585(7824):293-297. [Abstract]

Titration of CDK12-_Alexa488cycK (0-3.75 μM) to 50 nM _terbiumDDB1 in the presence of 5 μM THZ531, ATP or DMSO.
Cell

RNA Pol II inhibition activates cell death independently from the loss of transcription. [Abstract]

2025 Oct 30;188(22):6301-6316.e29. PMID: 40818455
Mol Cell

HSPA1A and DNAJB1 regulate NELF condensate dynamics to safeguard transcriptional recovery under heat stress. [Abstract]

2026 Feb 19;86(4):674-692.e10. PMID: 41653920
Mol Cell

A role for human senataxin in contending with pausing and backtracking during transcript elongation. [Abstract]

2025 Nov 20;85(22):4166-4182.e10. PMID: 41232527
Mol Cell

PAF1C-mediated activation of CDK12/13 kinase activity is critical for CTD phosphorylation and transcript elongation. [Abstract]

2025 May 15;85(10):1952-1967.e8. PMID: 40315851
Nat Commun

Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12. [Abstract]

2025 May 19;16(1):4656. PMID: 40389480

THZ531 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 19;16(1):4656. [Abstract]

Cell viability assay of primary human NUP98-rearranged AML cells, healthy donor BM MNC and CD34+ progenitors treated with indicated concentrations of THZ531 (0.1 nM-10 μM) for 3 days.

THZ531 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 19;16(1):4656. [Abstract]

GI₅₀ values from cell viability assays of murine AML cells treated with THZ531 for 3 days.

THZ531 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 19;16(1):4656. [Abstract]

RT-qPCR analysis of dTAG-NUP98::KDM5A cells treated with THZ531 (2 µM, 24 h) showing log2FC values.

THZ531 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 19;16(1):4656. [Abstract]

Representative images of γH2A.X immunofluorescence staining of dTAG-GFP-NUP98::KDM5A cells treated with THZ531 (2 µM, 24 h) (left) and quantification of γH2A.x signal (right). Midline represents the median, bounds of the box represent the inter-quartile range (Q1 to Q3), and whiskers represent minimum and maximum values.
Nat Chem Biol

Rational discovery of molecular glue degraders via scalable chemical profiling. [Abstract]

2020 Nov;16(11):1199-1207. PMID: 32747809
Nucleic Acids Res

Interaction of the NRF2 and p63 transcription factors promotes keratinocyte proliferation in the epidermis. [Abstract]

2021 Apr 19;49(7):3748-3763. PMID: 33764436
J Exp Clin Cancer Res

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma. [Abstract]

2023 Aug 21;42(1):214. PMID: 37599362
J Biomed Sci

O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage. [Abstract]

2022 Feb 14;29(1):13. PMID: 35164752
Pharmacol Res

CDK12 inhibition upregulates ATG7 triggering autophagy via AKT/FOXO3 pathway and enhances anti-PD-1 efficacy in colorectal cancer. [Abstract]

2024 Mar:201:107097. PMID: 38354870
Cell Death Dis

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer. [Abstract]

2021 Jul 27;12(8):740. PMID: 34315855
Cell Death Dis

CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells. [Abstract]

2020 Sep 15;11(9):754. PMID: 32934219
EMBO J

Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells. [Abstract]

2025 Sep 8. PMID: 40921851
Cell Rep

CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability. [Abstract]

2025 Nov 25;44(11):116495. PMID: 41176765
J Med Chem

3,5,7-Substituted Pyrazolo[4,3- d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders. [Abstract]

2022 Jul 14;65(13):8881-8896. PMID: 35749742
EMBO Rep

DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition. [Abstract]

2025 Jun;26(11):2836-2854. PMID: 40295725
Eur J Med Chem

Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer. [Abstract]

2023 Nov 5:259:115648. PMID: 37478560
Breast Cancer Res

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors. [Abstract]

2023 May 5;25(1):51. PMID: 37147730
Mol Oncol

CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1. [Abstract]

2024 May 22. PMID: 38775167
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
iScience

Transcriptional synergy in human aortic endothelial cells is vulnerable to combination p300/CBP and BET bromodomain inhibition. [Abstract]

2024 May 16;27(6):110011. PMID: 38868181
iScience

CDK12 regulates co-transcriptional splicing and RNA turnover in human cells. [Abstract]

2022 Aug 28;25(9):105030. PMID: 36111258
Cell Signal

Targeting CDK12 rescues C/EBPβ-mediated platinum and PARP inhibitor resistance in ovarian cancer. [Abstract]

2025 Dec 16:112328. PMID: 41412562
Glycobiology

Compromised CDK12 activity causes dependency on the high activity of O-GlcNAc transferase. [Abstract]

2024 Dec 10;34(12):cwae081. PMID: 39361894
Biochem Biophys Res Commun

Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA. [Abstract]

2024 Aug 28:735:150608. PMID: 39270556
Biochem Biophys Res Commun

Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma. [Abstract]

2019 Dec 10;520(3):544-550. PMID: 31615655
bioRxiv

2026 Feb 20.
Res Sq

2025 Dec 18.
bioRxiv

Defective Microhomology-Mediated End-joining in SMARCB1-Deficient Tumors. [Abstract]

2025 Nov 21:2025.11.20.689563. PMID: 41332615
bioRxiv

2025 March 19.
bioRxiv

Pol II degradation activates cell death independently from the loss of transcription. [Abstract]

2024 Dec 10:2024.12.09.627542. PMID: 39713309
bioRxiv

2023 Oct 22.
bioRxiv

2023 Jul 17.
Patent

US20230124700A1.
Harvard University

2023 Mar. 30487357.
bioRxiv

2023 Mar 23.
Universidade de Lisboa

2021 Dec 21.

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL (447.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7919 mL

8.9594 mL

17.9189 mL

5 mM

0.3584 mL

1.7919 mL

3.5838 mL

10 mM

0.1792 mL

0.8959 mL

1.7919 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.43 mg/mL (2.56 mM); Clear solution

This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.43 mg/mL (2.56 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.43 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.43 mg/mL (2.56 mM); Clear solution

This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

Cells are treated with THZ531 or DMSO for 6 hrs. Following treatment cells are washed 2-fold with cold PBS and then lysed in the following lysis buffer: 50 mM Hepes pH 7.4, 150 mM NaCl, 1% Nonidet P40 substitute, 5 mM EDTA, 1 mM DTT, and protease/phosphatase cocktails. Following clearance, lysates are treated with bio-THZ1 or bio-TH531 for pulldown overnight at 4°C. Lysates are further incubated at room temperature for 3 hrs to increase the efficiency of covalent bond formation. Lysates are then incubated with streptavidin agarose for pulldown for an additional 2 to 3 hrs at 4°C^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Jurkat cells are plated in 96-well plates at 20,000 cells/well in fresh media and treated with THZ531 or DMSO at the indicated concentrations for 72 hours. HAP1 cells are seeded in 96-well plates at 12,000 cells/well in fresh media and 24 hours later are treated with THZ531 at the indicated concentrations for 72 hours. Anti-proliferative effect of THZ531 is assessed. To assess the effect of inhibitor washout on anti-proliferation of Jurkat cells, cells are treated with THZ531 or DMSO for 6 hrs. Inhibitor-containing medium is then removed and incubated with or without THZ531 for 66 hrs. Anti-proliferative effect of THZ531 is assessed. All proliferation assays are performed in biological triplicate. IC₅₀s are determined using non-linear regression curve fit^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (643 KB)
- English - EN (643 KB)
- Français - FR (643 KB)
- Deutsch - DE (643 KB)
- Norwegian - NO (643 KB)
- Español - ES (643 KB)
- Swedish - SV (643 KB)
- Italian - IT (643 KB)
- Korean - KR (643 KB)
- Portuguese - PT (643 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang T, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7919 mL	8.9594 mL	17.9189 mL	44.7972 mL
	5 mM	0.3584 mL	1.7919 mL	3.5838 mL	8.9594 mL
	10 mM	0.1792 mL	0.8959 mL	1.7919 mL	4.4797 mL
	15 mM	0.1195 mL	0.5973 mL	1.1946 mL	2.9865 mL
	20 mM	0.0896 mL	0.4480 mL	0.8959 mL	2.2399 mL
	25 mM	0.0717 mL	0.3584 mL	0.7168 mL	1.7919 mL
	30 mM	0.0597 mL	0.2986 mL	0.5973 mL	1.4932 mL
	40 mM	0.0448 mL	0.2240 mL	0.4480 mL	1.1199 mL
	50 mM	0.0358 mL	0.1792 mL	0.3584 mL	0.8959 mL
	60 mM	0.0299 mL	0.1493 mL	0.2986 mL	0.7466 mL
	80 mM	0.0224 mL	0.1120 mL	0.2240 mL	0.5600 mL
	100 mM	0.0179 mL	0.0896 mL	0.1792 mL	0.4480 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

THZ531

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) THZ531

All CDK Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

THZ531

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) THZ531

All CDK Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

THZ531 Related Classifications

Cat. No.: HY-103618